Poxel Announces Participation at Several Upcoming Scientific and Investor Conferences

Oct. 27, 2020 16:45 UTC



LYON, France--(BUSINESS WIRE)-- Poxel SAS (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that members of the Poxel management and scientific team will participate at several upcoming scientific and investor conferences.

B. Riley Liver Disease Therapeutics Day
October 29, 2020 (virtual event)
David E. Moller, MD, Executive Vice President and Chief Scientific Officer, will participant in a panel session to discuss Poxel’s two NASH clinical-stage candidates, PXL770 and PXL065. PXL770 is a first-in-class, oral direct adenosine monophosphate-activated protein kinase (AMPK) activator. PXL065 is a novel, oral, proprietary deuterium-stabilized R-stereoisomer of pioglitazone.

DirectDirigeants Event
: November 3, 2020 (in-person conference)
Location: Paris
Thomas Kuhn, CEO of Poxel, will present a corporate update.

American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®
November 13-16, 2020 (virtual)
Members of Poxel’s scientific team will present three posters on PXL770 results and one poster on PXL065 results.

ALD Connect Annual Meeting
November 13-14, 2020 (virtual)
Members of Poxel’s scientific team will participate and present at this conference.

Bryan Garnier Healthcare Conference
November 16, 2020 (virtual)
Members of the Poxel management team will be available for one-on-one virtual meetings.

Jefferies Virtual London Healthcare Conference
November 17-19, 2020 (virtual); Poxel presentation: November 18th at 9:40-10:10 am EST / 2:40-3:10 pm GMT
Members of the Poxel management team will present a corporate overview and will be available for one-on-one virtual meetings. To access the webcast, please visit https://wsw.com/webcast/jeff141/poxel.pa/2381175. The webcast replay will remain available for 90 days following the live presentation.

Oddo Tech40 Digital Forum
November 24-25, 2020 (virtual)
Members of the Poxel management team will be available for one-on-one virtual meetings.

About Poxel SA
Poxel is a dynamic biopharmaceutical company that uses its extensive expertise in developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. Imeglimin, Poxel’s first-in-class lead product, targets mitochondrial dysfunction. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. A Japanese new drug application (J-NDA) is under review by the Pharmaceuticals and Medical Devices Agency (PMDA) to request approval for the manufacturing and marketing of Imeglimin for the treatment of type 2 diabetes. Poxel also established a partnership with Roivant Sciences for Imeglimin’s development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH. The Phase 2a trial met its primary endpoint and study objectives. PXL770 could also have the potential to treat additional metabolic diseases. PXL065 (deuterium-stabilized R-pioglitazone), a MPC inhibitor, is in a single Phase 2 trial for the treatment of NASH. Poxel also has additional earlier-stage programs from its AMPK activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: www.poxelpharma.com.

In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the Company is regularly reviewing the impact of the outbreak on its business.

As of the date of this press release, and based on publicly available information, the Company has not identified the occurrence of any material negative effect on its business due to the COVID-19 pandemic that remains unresolved. However, the Company anticipates that the COVID-19 pandemic could have further material negative impact on its business operations. The worldwide impact of COVID-19 may notably affect the Company’s internal organization and efficiency, particularly in countries where it operates and where confinement measures are implemented by the authorities. In addition, COVID-19 may impact market conditions and the Company’s ability to seek additional funding or enter into partnerships. Particularly, delays in the supply of drug substance or drug products, in the initiation or the timing of results of preclinical and/or clinical trials, as well as delays linked to the responsiveness of regulatory authorities could occur, which could potentially have an impact on the Company’s development programs and partnered programs. The Company will continue to actively monitor the situation.

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.


Poxel SA
Jonae R. Barnes
Senior Vice President, Investor Relations, Corporate Communication and Public Relations
+1 617 818 2985

Aurélie Bozza
Investor Relations and Communication Director
+33 6 99 81 08 36

Investor relations / Media - EU/US
Trophic Communications
Stephanie May or Valeria Fisher
may@trophic.eu or fisher@trophic.eu
+49 171 185 56 82 or +49 175 804 1816

Investor relations / Media - France
Emmanuel Huynh / Arthur Rouillé
+33 1 44 71 94 94


Source: Poxel SA

Back to news